PharmaTimes - March 2025

Smoke and mirrors

The other day I was in a shop, about to buy a Mars Bar and a can of Lilt for breakfast, when the gentleman in front of me – who was at least 70 – asked the shop worker for two ‘rhubarb and raspberry explosions’.

Initially my mind was unable to process the juxtaposition of the age group relative to the request. The conundrum, however, was resolved when a brace of garishly coloured disposable vapes was placed on the counter.

Whatever the circumstances, irrespective of the historical life choices which led to this moment, it didn’t seem like a very good day for self-care.

Vaping – 15 years after its emergence as the solution to our collective smoking crisis – is now having its own day of reckoning. Indeed, excessive use is causing a subculture of addicts who didn’t smoke in the first place and a toxic mountain of discarded hardware.

This is simply evidence that the NHS – which also prescribed cigarettes and alcohol during its illustrious history – was blindsided by the concept of exterminating one evil with a ‘slightly’ lesser evil.

Needless to say, I am now frequently asked about wejight loss drugs. Unlike e-cigarettes, which drifted into public consciousness in a pre-social media age, these have exploded into the mainstream, riding on a tsunami of TikTok tomfoolery.

And, yet, I believe that self-care can fly as long as we can strike the balance between relieving the burden of poor health and ‘rhubarb and raspberry explosions’.

Patient autonomy, backed up by tech and pharma innovation is the only answer to the restoration of public health.

A potentially, nearly perfect possibility in a historically imperfect world.

Enjoy the mag!

March 2025 - magazine highlights

That was the week that Wes…

Why the new public health ecosystem matters to pharma

Learning to make cocktails

Pharma’s Chris Henry learns he has Parkinson’s disease

Speed is good

Future of biopharma – notable shifts to watch out for

Next step navigation

Making accurate science stand out amid information explosi...

Barmy army?

Unlikely pathway in innovation may be the ultimate machine

Dual intentions

Hayley ponders our complicated relationship with ambition

Weight in vain?

The challenge of targeting chronic inflammation in obesity

What the doctor ordered?

Medication non-adherence is not only dangerous but expensi...